Immunocapture-liquid Chromatography/Mass Spectrometry in Simultaneous Quantification of Total Antibody and ADC for XMT-1522 in Human Plasma.

XMT-1522, an investigational antibody-drug conjugate (ADC) being developed by Mersana Therapeutics and Takeda, represents the first Dolaflexin®-based, cleavable ADC with a high drug-antibody ratio (DAR). Although the drug showed promise in Phase I clinical development, earlier this year Mersana and Takeda agreed to prioritize resources to focus on the advancement of another ADC, XMT-1536, a first-in-class ADC candidate targeting NaPi2b, ending the co-development collaboration for XMT-1522.

Pregabalin, (S)-3-(aminomethyl)-5-methylhexanoic acid, is an analog of the neurotransmitter gamma amino butyric acid (GABA), used for the treatment of peripheral and central neuropathic pain in adults and as adjunctive therapy for refractory partial seizures. The aim of this study is to develop a sensitive, specific, robust, and rapid LC-MS/MS method, using a simple extraction procedure with no interference from the matrix and with a short run time.

Sequencing the bacterial 16S rRNA gene is an established technique for assessing the phylogenetic diversity of microbial communities. This white paper discusses the methods and process to elucidate that Frontage’s QIIME2 analysis pipeline accurately estimates the composition of microbiome samples, as shown by the similarity to the theoretical abundance.